Plantable Health Announces the Opening of a New Multi-Center Clinical Trial with Memorial Sloan Kettering Cancer Center
New York, New York--(Newsfile Corp. - October 18, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces the opening of a new Clinical Trial, NUTRIVENTION-3, at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York with Dr. Urvi Shah as Principal Investigator. This trial follows on the back of the promising recently presented preliminary results for NUTRIVENTION study (NCT04920084). The primary objective for this trial is to evaluate the impact of Plantable intervention on stool butyrate levels present in the gut microbiome for patients with Myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS), and Smoldering Multiple Myeloma (SMM). Secondary endpoints of this trial evaluate BMI reduction, metabolic indicators including inflammatory markers, blood sugar and insulin markers, lipid markers and quality of life.
"We are delighted to announce the opening of a further clinical trial, with Plantable as the intervention arm, in this important clinical work. The microbiome, weight, and metabolic markers all have known, direct impact on chronic disease progression, and this study evaluates how those markers are impacting myeloma cancer. This important trial builds from the original NUTRIVENTION study, whose interim results were recently announced. NUTRIVENTION-3 now brings the Plantable intervention to a larger, multi-center audience at MSK and Emory University, which is an important next step in our path to being accredited for insurance coverage," said Dr. Nadja Pinnavaia, the Founder and CEO of Plantable.
The recent White House announcement now acknowledges Food as Medicine as a fundamental pillar for the reversal of diet-related chronic disease, supporting the expansion of the health insurers (government and private) to cover Food as Medicine services along with expanded coverage for nutrition counseling coverage. Plantable's clinical trials with clinically proven results enables Plantable to pursue insurance coverage from payers, while bringing providers, such as hospital systems, a turnkey solution for the reduction of metabolic markers associated with diet-related chronic disease, including some forms of cancer.
NUTRIVENTION 3 will begin recruitment in the coming two weeks. For more information on the clinical trials please refer to ClinicalTrials.gov.
About Plantable® Health Inc.
Plantable is a clinically supported, lifestyle intervention program that combines behavioral psychology, neuroscience, and nutritional science to transform health and wellness. Plantable drives healthy weight loss and an improvement in health, and well-being through effective behavior change. Plantable's efficacy is predicated upon the scientific foundation of plant-based nutrition, personalized coaching support and lifestyle educational tools to empower people to change their dietary habits. To view the Company's products and become a customer, please visit plantable.com or click the link here: https://plantable.com
If you are interested in investing in the Company and would like more information, please visit: https://www.plantable.com/investor-relations
On behalf of the Board of Directors,
Dr. Nadja Pinnavaia
Chief Executive Officer
For investor inquiries please contact:
Corporate Communications and Investor Relations
Cautionary Note Regarding Forward-Looking Information
Certain statements contained in this news release constitute forward-looking statements as defined under applicable securities laws. All statements in this news release, other than statements of historical facts, that address events or developments that management of the Company expect, are forward-looking statements. Specifically, the references in this news release to the benefits the Company expects to gain from NUTRIVENTION 3 constitute forward-looking statements. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements, see "Notice to Investors - Forward-Looking Information" and "Risk Factors" in the Prospectus. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, save and except as may be required by applicable securities laws.
SOURCE Plantable® Health Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140878